HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1--the patients' perspective.

Abstract
Excessive daytime sleepiness (EDS), of very similar pattern to that seen in narcolepsy syndrome, is extremely common in myotonic dystrophy type 1 (DM1). In a significant minority it has a profound disabling effect on employment, social functioning and activities of daily living. Limited published studies have shown inconsistent results from use of the psychostimulant drug modafinil. A recent European Medicines Agency (EMA) review concluded that on current evidence regarding safety and efficacy, modafinil's use should be restricted to the treatment of narcolepsy. In other conditions (although DM1 was not specifically considered) it was concluded that there was insufficient evidence of benefit to outweigh potentially serious side-effects, including severe skin reactions and cardiac arrhythmia. Clinicians with extensive experience in the management of DM1 have found modafinil to be extremely effective in appropriately selected patients with a very low incidence of serious side-effects. Given the recent EMA review, patients have expressed concern about the potential restriction of the use of modafinil in DM1. This brief review is an audit of the experience of a large group of patients and their clinicians concerning EDS and DM1 and concludes that despite the limited literature there is strong evidence to support the use of modafinil in carefully selected patients.
AuthorsD Hilton-Jones, M Bowler, H Lochmueller, C Longman, R Petty, M Roberts, M Rogers, C Turner, D Wilcox
JournalNeuromuscular disorders : NMD (Neuromuscul Disord) Vol. 22 Issue 7 Pg. 597-603 (Jul 2012) ISSN: 1873-2364 [Electronic] England
PMID22425060 (Publication Type: Journal Article)
CopyrightCopyright © 2012 Elsevier B.V. All rights reserved.
Chemical References
  • Benzhydryl Compounds
  • Central Nervous System Stimulants
  • Modafinil
Topics
  • Benzhydryl Compounds (therapeutic use)
  • Central Nervous System Stimulants (therapeutic use)
  • Disorders of Excessive Somnolence (drug therapy, etiology, psychology)
  • Female
  • Humans
  • Male
  • Modafinil
  • Myotonic Dystrophy (complications, epidemiology)
  • Surveys and Questionnaires
  • United Kingdom (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: